UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
| |
x | QUARTERLY REPORT UNDER TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2015 |
| |
OR |
| |
o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission file number 000-54754
THC Farmaceuticals, Inc.
(Exact Name of Small Business Issuer as specified in its charter)
UTAH
(State or other Jurisdiction of Incorporation or Organization)
7170 E. McDonald Dr., Ste 3
Scottsdale, Arizona 85253
(Address of principal executive offices)
(480) 725-9060
(Issuers telephone number, including area code)
Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days. YES x NO o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (SS 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES x NO o (The Registrant does not have a corporate Web site.)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 if the Exchange Act.
| | | | |
Large Accelerated Filer | o | | Accelerated Filer | o |
Non-accelerated Filer (Do not check if smaller reporting company) | o | | Smaller Reporting Company | x |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YES o NO x
APPLICABLE ONLY TO CORPORATE ISSUERS:
Indicate the number of shares outstanding of each of the issuers classes of common stock, as of the latest practicable date.
As of August 12, 2015, 14,996,600 shares of the registrants common stock were outstanding.
FORWARD LOOKING STATEMENTS
This Quarterly Report on Form 10-Q, Financial Statements and Notes to Financial Statements contains forward-looking statements that discuss, among other things, future expectations and projections regarding future developments, operations and financial conditions. All forward-looking statements are based on managements existing beliefs about present and future events outside of managements control and on assumptions that may prove to be incorrect. If any underlying assumptions prove incorrect, our actual results may vary materially from those anticipated, estimated, projected or intended
PART I FINANCIAL INFORMATION
ITEM 1.
FINANCIAL STATEMENTS
June 30, 2015
C O N T E N T S
-2-
THC FARMACEUTICALS, INC.
Condensed Consolidated Balance Sheets
June 30, 2015 and September 30, 2014
(Unaudited)
| | | | | | |
| | 06/30/2015 | | 9/30/2014 |
ASSETS | | | | | | |
| | | | | | |
Current Assets: | | | | | | |
Cash | | $ | 5,551 | | $ | 637 |
Accounts Receivable | | | 1,442 | | | 1,754 |
Deposits and Prepayments | | | 25,000 | | | 0 |
Total Current Assets | | | 31,992 | | | 2,391 |
Property plant & equipment net of accumulated depreciation of $10,525 and $9,472, respectively | | | 11,628 | | | 12,082 |
Intangible Assets | | | 255,159 | | | 33,677 |
Long Term Investments | | | 837,050 | | | 0 |
Loans Recievable, related party | | | 579,315 | | | 0 |
TOTAL ASSETS | | $ | 1,715,144 | | $ | 48,150 |
| | | | | | |
| | | | | | |
LIABILITIES AND STOCKHOLDERS' DEFICIT | | | | | | |
| | | | | | |
Current Liabilities: | | | | | | |
Related Party Accounts Payable | | $ | 0 | | $ | 900 |
Accounts Payable | | | 16,180 | | | 5,084 |
Current portion of long term debt - Related Party | | | 0 | | | 0 |
Total Current Liabilities | | | 16,180 | | | 5,984 |
Long Term Liabilities: | | | | | | |
Accrued Interest Related Party | | | 577 | | | 12,480 |
Notes Payable to Related Parties | | | 684,223 | | | 77,701 |
Total Long Term Liabilities | | | 684,800 | | | 90,181 |
Total Liabilities | | | 700,980 | | | 96,165 |
| | | | | | |
Stockholders' Equity/Deficit: | | | | | | |
Preferred Stock 10,000,000 shares authorized, par value $0.001 per share; with no shares issued and outstanding as of June 30, 2015 and September 30, 2014 | | | | | | |
Common Stock 90,000,000 shares authorized having a par value of $0.001 per share; 11,971,600 issued and outstanding as of June 30, 2015 and 8,968,000 shares issued and outstanding as of September 30, 2014 | | | 14,997 | | | 8,968 |
Additional Paid-in Capital | | | 1,202,847 | | | 83,875 |
Accumulated Deficit | | | (203,680) | | | (140,858) |
Total Stockholders' Equity | | | 1,014,164 | | | (48,015) |
| | | | | | |
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | | $ | 1,715,144 | | $ | 48,150 |
The accompanying notes are an integral part of these condensed consolidated financial statements.
-3-
THC FARMACEUTICALS, INC.
Condensed Consolidated Statements of Operations
For the Three Months and Nine Months Ended June 30, 2015 and 2014
(Unaudited)
| | | | | | | | | | | |
| For the Three Months Ended June 30, 2015 | | For the Three Months Ended June 30, 2014 | | For the Nine Months Ended June 30, 2015 | | For the Nine Months Ended June 30, 2014 |
Revenues | | | | | | | | | | | |
Revenues from transaction fees | $ | 4,501 | | $ | 4,368 | | $ | 13,733 | | $ | 14,248 |
Total Revenues | | 4,501 | | | 4,368 | | | 13,733 | | | 14,248 |
| | | | | | | | | | | |
Operating Expenses | | | | | | | | | | | |
General and Administrative | | 35,236 | | | 4,005 | | | 65,151 | | | 21,458 |
Depreciation | | 151 | | | 150 | | | 454 | | | 449 |
Service, related party | | 4,500 | | | 2,700 | | | 11,400 | | | 9,600 |
Total Operating Expense | | 39,887 | | | 6,855 | | | 77,010 | | | 31,507 |
Operating Loss | | (35,387) | | | (2,487) | | | (63,277) | | | (17,258) |
Interest Expense, finance of ATMs | | 0 | | | 0 | | | 0 | | | 55 |
Interest Expense, related party | | 304 | | | 1,765 | | | 575 | | | 4,763 |
Net Loss | $ | (35,690) | | $ | (4,252) | | $ | (63,852) | | $ | (22,076) |
Loss per Common Share - Basic & Diluted | $ | (0.01) | | $ | (0.01) | | $ | (0.01) | | $ | (0.01) |
Weighted Average Shares Outstanding - Basic & Diluted | | 14,996,600 | | | 8,968,000 | | | 14,996,600 | | | 8,968,000 |
The accompanying notes are an integral part of these condensed consolidated financial statements.
-4-
THC FARMACEUTICALS, INC.
Condensed Consolidated Statements of Cash Flows
For the Three Months Ended June 30, 2015 and 2014
(Unaudited)
| | | | | |
| For the Nine Months Ended June 30, 2015 | | For the Nine Months Ended June 30, 2014 |
Cash Flows From Operating Activities | | | | | |
Net Loss | $ | (63,852) | | $ | (22,076) |
Adjustments to reconcile net loss to net cash from operating activities: | | | | | |
Adjustments to Prepaid Expenses and Other Assets | | (25,000) | | | |
Depreciation | | 454 | | | 449 |
(Increase)/Decrease in accounts receivable | | 312 | | | 355 |
Increase/(Decrease) in accounts payable | | 10,198 | | | 100 |
Loans Recievable, related party | | (579,315) | | | 0 |
Business Holding | | (837,050) | | | |
Accrued interest on related party loan | | (11,903) | | | 4,764 |
Net Cash from Operating Activities | | (1,506,156) | | | (16,408) |
| | | | | |
Cash Flows from Investing Activities | | | | | |
Investement in Intellectual Property | | (8,532) | | | 0 |
Net Cash Flows from Investing Activities | | (8,532) | | | 0 |
| | | | | |
Cash Flows from Financing Activities | | | | | |
(Increase)/Decrease in intangible assets | | (212,950) | | | 0 |
Principal payments on Notes Payable | | (77,701) | | | (1,839) |
Proceeds from notes payable to related parties | | 684,223 | | | 19,600 |
Financed ATMs | | (2) | | | |
Capital Stock | | 6,029 | | | 0 |
Paid in Capital | | 1,118,971 | | | 0 |
Retained Earnings | | 1,031 | | | 19,600 |
Net Cash from Financing Activities | | 1,519,601 | | | 17,761 |
| | | | | |
Net Increase/(Decrease) in Cash | | 4,913 | | | 1,353 |
Beginning Cash Balance | | 638 | | | 579 |
Ending Cash Balance | $ | 5,550.30 | | $ | 1,932 |
| | | | | |
| | | | | |
Supplemental Disclosure of Cash Flow Information | | | | | |
Cash paid during the period for interest | $ | 0 | | $ | 55 |
Cash paid during the period for taxes | $ | 0 | | $ | 100 |
Assets acquired in exchange for related party debt | $ | - | | $ | - |
The accompanying notes are an integral part of these condensed consolidated financial statements.
-5-
THC FARMACEUTICALS, INC.
Notes to Condensed Consolidated Financial Statements
June 30, 2015
NOTE 1 - CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at June 30, 2015, and for all periods presented herein, have been made.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed consolidated financial statements be read in conjunction with the financial statements and notes thereto included in the Companys Annual Report on Form 10-K for the year ended September 30, 2014. The results of operations for the three-month period ended June 30, 2015 are not necessarily indicative of the operating results for the full year.
NOTE 2 SIGNIFICANT ACCOUNTING POLICIES
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Recent Accounting Pronouncements
The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its consolidated results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its condensed consolidated financial statements.
NOTE 3 RELATED PARTY TRANSACTIONS / SERVICE AGREEMENT
The Company has a Service Agreement with Wasatch ATM (Wasatch), a Utah limited liability corporation owned and managed by a Company stockholder. The agreement provides for Wasatch to provide all maintenance, repair and service work along with distribution of vault cash. Since December 1, 2014, Wasatch has been compensated at a rate of $1,500 per month. The fee paid to Wasatch may be subject to change.
NOTE 4 - RELATED PARTY TRANSACTIONS / LONG-TERM DEBT
On June 30, 2015, the Company owed $104,908 in related party long-term debt and $924 related party accrued interest.
NOTE 5 - SUBSEQUENT EVENTS
None.
NOTE 6 COST OF INVESTMENTS
During the quarter ended June 30, 2015, the Company acquired 8,745,000 shares of Rocky Mountain Ayre, Inc. (RMTN) in exchange for the majority of the Companys hempcoin assets. This transaction was recorded at fair market value based upon the market value of the RMTN shares. This was not a related party transaction.
During the quarter ended March 31, 2015, the Company acquired a 30% interest in Las Vegas Cannabis Info Center, Inc. in exchange for $25,000 cash and 25,000 shares of the Companys common stock valued at $1 per share. This transaction was booked at Fair Market Value based upon the market price of the Companys common stock and value of the consideration paid.
Since these investments exceed 20% and/or allow us to exercise significant influence over management, the Company is following the guidance of ASC 323 for the equity method of recording investments.
-6-
ITEM 2.
MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION.
When used in this Annual Report, the words may, will, expect, anticipate, continue, estimate, project, intend, and similar expressions are intended to identify forward-looking statements within the meaning of Section 27a of the Securities Act and Section 21e of the Exchange Act regarding events, conditions, and financial trends that may affect Guides future plans of operations, business strategy, operating results, and financial position. Persons reviewing this Annual Report are cautioned that any forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties and actual results may differ materially from those included within the forward-looking statements as a result of various factors. Such factors are discussed further below under Trends and Uncertainties, and also include general economic factors and conditions that may directly or indirectly impact our financial condition or results of operations.
Plan of Operation
Our primary focus during 2014 was the placement and servicing of ATM machines for public use along the Wasatch Front in the State of Utah. During the quarter ended June 30, 2015, we had a total of eight machines in operation and all eight machines remain in operation as of the quarter ended June 30, 2015. The Companys primary focus now, however, is on hemp and natural products, plus where feasible technology and ancillary products and services for the medical marijuana and legal recreational marijuana industry.
With the recent addition of Ed Rosenthal as the Companys president, the Company has begun research on plant terpenes and is investigating the feasibility and marketability of terpene based natural products. The Company intends to acquire and/or develop hemp based products in 2015.
During the quarter ended June 30, 2015, the Company sold the majority of its hempcoin assets Rocky Mountain Ayre, Inc. (RMTN) in exchange for an approximate 8,745,000 shares of RMTN. We believe the transaction brings value to the Company through ownership of RMTN and the Companys continued ownership approximately 899,074,298 Hempcoins (HMP). Additionally, the Company plans to expand into related additional areas they believe would be profitable for the Company and benefit its shareholders. One such area is the cultivation and sale of industrial hemp.
Presently, the Company does not have sufficient funds, without additional equity or debt financing to support operations for the next fiscal year. There is presently no commitment to provide any further funding to the Company. Given our current lack of liquidity and difficulty in obtaining debt from traditional banking sources, we will focus future fund raising on the sale of our equity securities. There can be no assurance that we will be successful at raising additional capital and without additional capital, we will not be able to expand operations and reach long term profitability.
Results of Operations
Three Months Ended June 30, 2015 Compared to Three Months Ended June 30, 2014
During the three months ended June 30, 2015, we recognized $4,501 in revenues. During the three months ended June 30, 2014, we recognized $4,368 in revenues. The increase in revenue for the period ended 2015 over the same period in 2014, appears to be attributable to a slight increase in consumer demand for cash transactions, possibly created by an improving economy and tourism industry in Utah.
We had a net loss for the three months ended June 30, 2015, of $35,387 and a net loss of $4,252 for the three months ended June 30, 2014. The loss for the quarter ended June 30, 2015 was more than the loss which occurred during the same quarter in 2014, primarily due to increases in general and administrative expenses during the quarter ended June 30, 2015 from increased staffing, planning and consulting activities and commencement of our terpene research.
We will need additional capital to expand operations and anticipate seeking both debt and equity capital in 2015. Additionally, as our business operations are only beginning, it is difficult to predict our ability to generate sufficient revenue to generate positive cash flows. Currently our biggest expenses are related to general and administrative costs consisting mainly of employee compensation which was $17,000 for the three months ended June 30, 2015 and $0 for the three months ended June 30, 2014. Our service fee to maintain ATM cash levels and operating functionality is $1,500 per month. We anticipate these fees remaining constant during 2015; however, that could change based upon market conditions.
-7-
Nine Months Ended June 30, 2015 Compared to Nine Months Ended June 30, 2014
During the nine months ended June 30, 2015, we recognized $13,733 in revenues. During the nine months ended June 30, 2014, we recognized $14,249 in revenues. The nominal decrease in revenue for the period ended 2015 over the same period in 2014 may be attributed to a decrease in consumer demand for cash transactions during the this first few months of this year.
We had a net loss for the nine months ended June 30, 2015, of $63,852 and a net loss of $22,076 for the nine months ended June 30, 2014. Our net loss for the 2015 period was the result of increased employee expense and the commencement of research activities in the areas of hemp and natural products.
Liquidity and Capital Resources
We had $5,551 cash or cash equivalents on hand as of June 30, 2015.
For the quarter ending June 30, 2015, the Company owed $684,223 to related parties for loans made to the Company.
The Company has accumulated losses of 203,680. As previously discussed above, managements plans include a review of the ATM business model and the addition of new business units in order to improve our cash flows and profitability. Without further related party funding or outside investment, the Company will not have sufficient capital to fund operations for the next 12 months.
Off-Balance Sheet Arrangements
We had no Off-Balance Sheet arrangements during the quarter ended June 30, 2015.
ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.
ITEM 4.
CONTROLS AND PROCEDURES.
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including the Principal Executive Officer and Principal Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures as required by Exchange Act Rule 13a-15(b) as of the end of the period covered by this report. Based on that evaluation, the Principal Executive Officer and Principal Financial Officer have concluded that as of June 30, 2015, and as of the date that the evaluation of the effectiveness of our disclosure controls and procedures was completed, our disclosure controls and procedures were not effective to satisfy the objectives for which they are intended.
Management believes that, as of June 30, 2015, the Companys internal control over financial reporting was ineffective, due to the following material weaknesses listed below:
Limited personnel; Reliance on third party. During the fiscal quarter, our only personnel resources were the Companys former president, chief executive officer, our treasurer and a third party accounting vendor. We have terminated the accounting vendor during the fiscal quarter. The Company has now brought the accounting function directly under the CFO and hired an outside accounting advisor. However, even with these additions, the company remains minimally staffed and has limited funds for staffing. This could result in future errors or material misstatements.
Lack of Adequate Controls and Procedures. The Company lacks adequate controls and procedures. Additionally, management has not developed and effectively communicated to our employees its accounting policies and procedures. This has resulted in inconsistent practices.
These control deficiencies could result in a material misstatement to our interim or annual financial statements that possibly would not be prevented or detected.
-8-
When we are financially able, we intend to take appropriate and reasonable steps to make the necessary improvements to remediate these deficiencies and we intend to consider the results of our remediation efforts and related testing as part of our next assessment of the effectiveness of our internal control over financial reporting.
Changes in Internal Control Over Financial Reporting
There was no change in our internal control over financial reporting that occurred during the three months ended June 30, 2015 that has materially affected, or is reasonably likely to materially affect our internal control over financial reporting, except for the on-going efforts to address the significant deficiencies identified above.
PART II. OTHER INFORMATION
ITEM 1.
LEGAL PROCEEDINGS.
None.
ITEM 1A.
RISK FACTORS.
We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.
ITEM 2.
UNREGISTERED SALE OF EQUITY SECURITIES.
None.
ITEM 3.
DEFAULTS UPON SENIOR SECURITIES.
None.
ITEM 4.
MINE SAFETY DISCLOSURES.
None.
ITEM 5.
OTHER INFORMATION.
None.
-9-
ITEM 6.
EXHIBITS.
The following documents are included herein:
| | | | | |
Exhibit | | Incorporated by reference | Filed |
Number | Document Description | Form | Date | Number | herewith |
2.1 | Articles of Incorporation, as amended | S-1 | 12/30/10 | 2.1 | |
| | | | | |
2.2 | Bylaws | S-1 | 12/30/10 | 2.2 | |
| | | | | |
2.3 | Agreement and Plan of Merger | S-1 | 12/30/10 | 2.3 | |
| | | | | |
2.4 | Articles of Amendment | 8-K | 03/19/15 | 2.4 | |
| | | | | |
10.1 | RMTN Agreement | 8-K | 06/01/15 | 10.1 | |
| | | | | |
21.1 | List of Subsidiaries | S-1 | 12/30/10 | 21.1 | |
| | | | | |
31.1 | Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | | | | X |
| | | | | |
31.2 | Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | | | | X |
| | | | | |
32.1 | Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 for the Chief Executive Officer | | | | X |
| | | | | |
32.2 | Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 for the Chief Financial Officer | | | | X |
| | | | | |
101.INS | XBRL Instance Document | | | | X |
| | | | | |
101.SCH | XBRL Taxonomy Extension Schema | | | | X |
| | | | | |
101.CAL | XBRL Taxonomy Extension Calculations | | | | X |
| | | | | |
101.DEF | XBRL Taxonomy Extension Definitions | | | | X |
| | | | | |
101.LAB | XBRL Taxonomy Extension Labels | | | | X |
| | | | | |
101.PRE | XBRL Taxonomy Extension Presentation | | | | X |
-10-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following person on behalf of the Registrant and in the capacities on this 18th day of August, 2015.
| | |
| THC FARMACEUTICALS, INC. |
| | |
| BY: | MIKE GRAVEL |
| | Mike Gravel |
| | Cheif Executive Officer and Director |
| | |
| BY: | JON McGEE |
| | Jon McGee |
| | Principal Financial Officer, Principal Accounting Officer, Treasurer and Director |
-11-
EXHIBIT 31.1
CERTIFICATION
I, Mike Gravel, certify that:
1.
I have reviewed this report on Form 10-Q of THC Farmaceuticals, Inc.
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrants other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and
5.
The registrants other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of registrants board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting.
| | |
Date: August 18, 2015 | | /s/ Mike Gravel |
| | Mike Gravel |
| | Chief Executive Officer |
EXHIBIT 31.2
CERTIFICATION
I, Jon McGee, certify that:
1.
I have reviewed this report on Form 10-Q of THC Farmaceuticals, Inc.
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrants other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and
5.
The registrants other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of registrants board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting.
| | |
Date: August 18, 2015 | | /s/ Jon McGee |
| | Jon McGee |
| | Chief Financial Officer |
EXHIBIT 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of THC Farmaceuticals, Inc. (the Company) on Form 10-Q for the period ending June 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Mike Gravel, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:
(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
IN WITNESS WHEREOF, the undersigned has executed this certification as of the 18th day of August, 2015.
/s/ Mike Gravel
Mike Gravel
Chief Executive Officer
EXHIBIT 32.2
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of THC Farmaceuticals, Inc. (the Company) on Form 10-Q for the period ending June 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Jon McGee, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:
(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
IN WITNESS WHEREOF, the undersigned has executed this certification as of the 18th day of August, 2015.
/s/ Jon McGee
Jon McGee
Chief Financial Officer
THC Farmaceuticals (PK) (USOTC:CBDG)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
THC Farmaceuticals (PK) (USOTC:CBDG)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025